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Introduction: Elderly patients constitute the majority of patients 
with advanced non–small-cell lung cancer (NSCLC). The median 
age of newly diagnosed patients with lung cancer in the United 
States is approximately 70 years. Despite this, the elderly are signifi-
cantly underrepresented in clinical trials. This has led to increasing 
uncertainty as to their optimal treatment. Here, we seek to determine 
the proportion of elderly patients in key phase III clinical trials in 
advanced NSCLC.
Methods: A literature search for all phase III trials of systemic ther-
apy for advanced NSCLC between 1980 and 2010 was performed 
using PubMed. The 100 most highly cited trials were then deter-
mined using the “Web of Science” application. The inclusion criteria 
and results of each of these studies were examined for the exclusion 
of elderly patients, median patient age, and age range.
Results: A total of 248 trials were reviewed. Among the 100 most 
cited trials, 33% specifically excluded elderly patients in their trial 
design (age exclusion ranged from >65 to >75 years of age). The 
average-reported patient median age in these trials was 60.9 years. 
The average age for trials that did not exclude elderly patients was 
not significantly different at 61.0 (p = 0.97). The average median age 
of patients was 61 years (95% confidence interval (CI): 60.4–61.6) 
in all trials.
Conclusion: Elderly patients are significantly underrepresented in 
these recent key practice-defining trials. Greater representation of 
elderly patients in phase III trials is required to better define evi-
dence-based treatment paradigms in the increasingly elderly NSCLC 
population.
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The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased 
over the recent years and is presently 70 years.1,2 The emer-
gence of advanced NSCLC as a disease of the elderly has 
occurred concomitantly with the establishment of chemother-
apy and targeted therapies as its primary treatment. The bene-
fit of these has been demonstrated in many large-scale clinical 
trials involving thousands of patients. However, many of these 
trials have been criticized as underrepresenting or even exclud-
ing elderly patients. The treatment of elderly patients with 
advanced NSCLC is thus often extrapolated from the results 
of clinical trials involving younger patients. The generaliz-
ability of trials involving younger patients to an elderly real-
world population has been challenged given the differences in 
comorbidity, functional status, toxicity, and pharmacokinetics 
associated with increasing age.3–5 Perhaps more concerning is 
that emerging evidence suggests that elderly patients are often 
undertreated compared with younger patients6; a situation that 
is conceivably secondary to a lack of data on their optimal 
treatment. Given the increasing age of patients with advanced 
NSCLC and the apparent underrepresentation of the elderly in 
clinical trials in this area, an urgent need for elderly specific 
data exists and has led to the emergence of a small number of 
elderly-only trials seeking to validate current practice in the 
elderly.7–11
In this study, we investigated the degree to which exclu-
sion or underrepresentation of the elderly occurs in practice-
changing clinical trials in advanced NSCLC.
METHODS
An extensive literature search for all phase III 
randomized controlled clinical trials involving systemic 
therapy for advanced NSCLC was performed using the PubMed 
clinical queries application (Supplementary Appendix A, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A383). Professional oncology society guidelines were also 
screened to ensure that no cited trials were overlooked by the 
aforementioned search strategy (Supplementary Appendix A, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A383). Studies were deemed eligible for inclusion in this 
review if they were phase III, involved systemic therapy alone, 
studied advanced NSCLC, and were conducted between 
1980 and 2010. Elderly-only studies were excluded from our 
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analysis. A total of 248 eligible studies were identified, and 
their full text was reviewed by the authors. Of these studies, 
38 were found to be ineligible on the basis of involving SCLC 
(n = 3), non-advanced NSCLC (n = 5), surgery/radiotherapy 
(n = 6), or non-phase III trial design (n = 11), or if they were 
subgroup analyses of already included studies (n = 13). The 
number of citations for each of the remaining 210 trials 
was then determined using the Web of Science application. 
The 100 most cited studies were identified and re-reviewed. 
The median age, age range, and any age-related exclusion/
inclusion criteria were recorded for each trial (Fig. 1). The 
average median study age and its associated 95% confidence 
interval (CI) were calculated using a bootstrapping method 
with 1000 bootstrap samples. The median age of studies 
that overtly excluded the elderly was compared with studies 
without exclusion using the Wilcoxon–Mann–Whitney rank 
sum test. Studies were grouped according to the decade of 
publication. The trend over three decades was tested using 
Cochran–Armitage trend test.
RESULTS
A total of 248 phase III trials in advanced NSCLC were 
identified, and upon detailed review, 210 trials were eligible for 
inclusion in this study. Among these trials, the 100 most cited 
studies were identified and further analyzed (Supplementary 
Appendix A). The median sample size of these trials was 
368 patients (range, 40–1725). They were published between 
1985 and 2010, with eight studies before 1990, 28 studies 
from 1991 to 2000, and 64 studies from 2001 to 2010. Of 
these trials, 33 overtly excluded elderly patients with age-
based exclusion criteria of either greater than 70 years (n = 6) 
or 75 years (n = 27) of age. When analyzed by decade, 75% (6 
of 8) of trials overtly excluded the elderly during 1981–1990, 
36% (10 of 28) during 1991–2000, and 27% (17 of 64) during 
2001–2010 (Fig. 2, trend test p = 0.02). Despite this appar-
ent decrease in the percentage of trials excluding the elderly 
over time, there was no significant change in the median age 
of trial patients. The average-reported median age were 59.3 
years, 60.3 years, and 61.5 years for trials published in 1981–
1990, 1991–2000, and 2001–2010, respectively (p = 0.07, 
Fig. 3).
The average median age of patients in all trials was 61 
years (95% CI: 60.4–61.6), 60.9 years (95% CI: 59.9–62) in 
trials that overtly excluded the elderly, and 61 years (95% CI: 
60.2–61.8) in trials that did not. The upper 95% confidence 
limits were 61.6, 62.0, and 61.8, respectively. All of them were 
lower than the median general patient population age of 70 
years. There was no significant difference in the median age 
of patients between trials that excluded the elderly and those 
that did not (p = 0.97) (Fig. 4). Finally, there were only three 
studies that had a median age greater than 69.
DISCUSSION
This study contributes to a growing body of literature 
indicating that elderly patients are underrepresented in clini-
cal trials; specifically those investigating novel therapies for 
advanced NSCLC.12–14 Here, we have clearly demonstrated 
that a significant proportion of highly cited phase III clini-
cal trials in advanced NSCLC overtly exclude elderly patients. 
Although the overt exclusion of elderly patients is decreas-
ing with time, this has not significantly affected the median 
age of patients in these trials. Furthermore, the median age 
of patients in these trials does not differ significantly between 
trials that specifically exclude the elderly and those that do 
not and is much lower than the median age of patients with 
advanced NSCLC in general.
FIGURE 1.  Flow diagram of the 
study protocol.
FIGURE 2.  The percentage of studies by decade, 
which explicitly exclude elderly patients among the 
100 most cited phase III clinical trials in the treat-
ment of advanced NSCLC. NSCLC, non–small-cell 
lung cancer.
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The significant underrepresentation of elderly patients 
that we have uncovered in these studies logically draws into 
question the generalizability of their results to elderly patients. 
Elderly patients often harbor increased comorbidities and 
have poorer glomerular filtration rate,3,5 hepatic,4 and bone 
marrow reserve,15 resulting in altered pharmacokinetics and 
increased toxicity from treatment. As such, therapies demon-
strated to be efficacious in a significantly younger group of 
trial patients may not necessarily be effective in an increas-
ingly elderly population of patients with advanced NSCLC. 
Furthermore, quality of life in an older patient population is 
potentially more complex, and the impact of palliative che-
motherapy on this important clinical end point in the elderly 
population is poorly understood. Thus, the balance of toxicity 
against the antitumor effect of these treatments and their effect 
on survival and quality of life may be significantly altered in 
an elderly real-world population.
This study also reveals a more concerning dimension 
of the underrepresentation of the elderly in advanced NSCLC 
clinical trials: that the most highly cited and practice-changing 
trials in the field are the ones that we have shown to exclude 
elderly patients. The implication that the current treatment 
of advanced NSCLC is based on trials that largely exclude 
the same elderly patients who account for a large proportion 
of the population with advanced NSCLC is sobering. As 
such, we propose a greater emphasis be placed on recruiting 
clinical trial patients with age demographics that better 
represent the median age of the advanced NSCLC population. 
Our group has participated in many of the trials cited in this 
study and as such has adopted a policy of requesting that any 
formal exclusion of elderly patients be removed from trials 
conducted at our institution. Further investigation to identify 
specific barriers to the inclusion of elderly patients in clinical 
trials will be needed. Greater criticism should also be levied 
against future trials that fail to meet this standard, or worse, 
overtly exclude elderly patients. Until this normalization of 
trial patient age is achieved, we believe it is appropriate to 
continue to conduct elderly-only trials to validate current 
practice in the treatment of elderly patients despite the 
expense of such trials.7–11
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FIGURE 3.  The average median age of patients in highly 
cited phase III trials in advanced NSCLC by decade. There 
were four trials with a median patient age greater than 65 
(○). NSCLC, non–small-cell lung cancer.
FIGURE 4.  The average median age of patients in the 100 
most cited phase III clinical trials in advanced NSCLC compared 
with the general population (---). NSCLC, non–small-cell 
lung cancer.
